Association de Formation Médicale Continue - Formation et Informations Médicales - ---------au service des professionnels de santé et de la santé ------------ depuis 1974
2 Mars 2008
Résultats des analyses comparatives des données de 3.886 hommes atteints d'un CP à celles de 6.438 témoins :
aucune association n'a été trouvée entre le risque de CP et les concentrations sériques
de testostérone,
de testostérone libre calculée,
de dihydrotestostérone,
de dihydroépiandrosterone,
d'androstènedione,
d'androstanediol,
d'estradiol, ou
d'estradiol libre.
-Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studiesr.
Endogenous Hormones, Prostate Cancer Collaborative Group
Correspondence to: Andrew W. Roddam, D.Phil, Cancer Research UK Epidemiology Unit, University of Oxford, Richard Doll Building, Oxford, UK, OX3 7LF (e-mail: andrew.roddam@ceu.ox.ac.uk).
Background: Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. We performed a collaborative analysis of the existing worldwide epidemiologic data to examine these associations in a uniform manner and to provide more precise estimates of risks.
Methods: Data on serum concentrations of sex hormones from 18 prospective studies that included 3886 men with incident prostate cancer and 6438 control subjects were pooled by the Endogenous Hormones and Prostate Cancer Collaborative Group. Relative risks (RRs) of prostate cancer by fifths of serum hormone concentration were estimated by use of conditional logistic regression with stratification by study, age at recruitment, and year of recruitment. All statistical tests were two-sided.
Results: No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol. The serum concentration of sex hormone–binding globulin was modestly inversely associated with prostate cancer risk (RR in the highest vs lowest fifth = 0.86, 95% confidence interval = 0.75 to 0.98; Ptrend = .01). There was no statistical evidence of heterogeneity among studies, and adjustment for potential confounders made little difference to the risk estimates.
Conclusions: In this collaborative analysis of the worldwide data on endogenous hormones and prostate cancer risk, serum concentrations of sex hormones were not associated with the risk of prostate cance